Literature DB >> 29205758

Transanal endoscopic microsurgery: a New Zealand experience.

Ian Bloomfield1, Roelof Van Dalen1, Simione Lolohea1, Linus Wu1.   

Abstract

BACKGROUND: Transanal endoscopic microsurgery (TEMS) is a proven alternative therapy to either radical surgery or endoscopic mucosal resection for rectal neoplasms. It has proven benefits with lower morbidity and mortality compared with total mesorectal excision, and a lower local recurrence rate when compared to endoscopic mucosal techniques.
METHODS: A retrospective data collection of TEMS procedures performed through Waikato District Health Board, New Zealand, from 2010 to 2015 was conducted. Supportive follow-up data were sourced from patient records and from local centres around New Zealand.
RESULTS: A total of 137 procedures were performed over the study period, with five being repeat procedures. Procedures were mostly performed for benign lesions (66.4%) with an overall complication rate of 15.3%, only five of which were Clavien-Dindo grade III (3.6%). Our local recurrence rate after resection of benign lesions was 5.1%.
CONCLUSION: Our data set demonstrates the TEMS procedure to be safe compared to radical resection (total mesorectal excision) for sessile rectal lesions. Close endoscopic follow-up is recommended, especially for close or incomplete margins. Good therapeutic results can be obtained for appropriately selected early malignant lesions. TEMS provides better oncological results than endoscopic mucosal resection or transanal excision.
© 2017 Royal Australasian College of Surgeons.

Entities:  

Keywords:  New Zealand; microsurgery; polyp; rectal neoplasm; retrospective study

Mesh:

Year:  2017        PMID: 29205758     DOI: 10.1111/ans.14142

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  1 in total

1.  Transanal endoscopic microsurgery in very large and ultra large rectal neoplasia.

Authors:  X Serra-Aracil; R Flores-Clotet; L Mora-López; A Pallisera-Lloveras; S Serra-Pla; S Navarro-Soto
Journal:  Tech Coloproctol       Date:  2019-08-28       Impact factor: 3.781

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.